Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP

Shaoman Yin, Štefan Kaluz, Narra S. Devi, Adnan Abdul Jabbar, Rita G. de Noronha, Ji-Young Mun, Zhaobin Zhang, Purushotham R. Boreddy, Wei Wang, Zhibo Wang, Thomas J. Abbruscato, Zhengjia Chen, Jeffrey J. Olson, Ruiwen Zhang, Mark M. Goodman, Kyriaco C. Nicolaou, Erwin G. Van MeirClinical 2012 · DOI

Abstract

Our results suggest that the new HIF pathway inhibitor KCN1 has antitumor activity in mouse models, supporting its further translation for the treatment of human tumors displaying hypoxia or HIF overexpression.
BibTeX
@inproceedings{yin2012arylsulfonamide,
  author = {Shaoman Yin and Štefan Kaluz and Narra S. Devi and Adnan Abdul Jabbar and Rita G. de Noronha and Ji-Young Mun and Zhaobin Zhang and Purushotham R. Boreddy and Wei Wang and Zhibo Wang and Thomas J. Abbruscato and Zhengjia Chen and Jeffrey J. Olson and Ruiwen Zhang and Mark M. Goodman and Kyriaco C. Nicolaou and Erwin G. Van Meir},
  title = {{Arylsulfonamide KCN1 Inhibits <i>In Vivo</i> Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP}},
  booktitle = {Clinical},
  year = {2012},
  doi = {10.1158/1078-0432.ccr-12-0861},
}

Loading related content...

Figure